ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc (ZNTL)

3,61
-0,02
(-0,55%)
Fermé 30 Novembre 10:00PM
3,61
0,00
(0,00%)
Après les heures de négociation: 11:00PM

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
3,61
Prix Achat
3,56
Prix Vente
3,68
Volume échangé
423 855
3,60 Fourchette du Jour 3,73
2,66 Plage de 52 semaines 18,07
Cap du marché
Clôture Veille
3,63
Ouverture
3,69
Dernière Transaction
15
@
3.68
Dernière heure de transaction
Volume financier
US$ 1 551 593
VWAP
3,6607
Volume moyen (3 m)
2 172 314
Actions en circulation
71 265 400
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,88
Bénéfice par action (BPA)
-4,1
Chiffre d'affairess
-
Bénéfice net
-292,19M

À propos de Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets a... Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
Siège social
Wilmington, Delaware, USA
Fondé
-
Zentalis Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ZNTL. Le dernier cours de clôture d'Zentalis Pharmaceuticals était de US$3,63. Au cours de la dernière année, les actions de Zentalis Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 2,66 à US$ 18,07.

Zentalis Pharmaceuticals compte actuellement 71 265 400 actions en circulation. La capitalisation boursière d'Zentalis Pharmaceuticals est de US$258,69 million. Zentalis Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -0.88.

ZNTL Dernières nouvelles

Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib

Julie Eastland appointed Chief Executive Officer, President and Director Ingmar Bruns, M.D., appointed Chief Medical Officer Scott Myers appointed to the Board of Directors as Chairperson SAN...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, Sept. 16, 2024 NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.4112.81253.23.73.088587173.36676815CS
40.8731.75182481752.744.442.7114042453.56428907CS
120.3611.07692307693.255.442.6621723143.56197053CS
26-7.89-68.608695652211.5132.6617530824.06674867CS
52-6.98-65.911237016110.5918.072.6612813426.95647095CS
156-73.39-95.31168831177785.952.6687862816.76407589CS
260-21.08-85.378695828324.6987.192.6665754621.4429912CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BSLKBolt Projects Holdings Inc
US$ 0,71
(139,86%)
80,81M
PRZOParaZero Technologies Ltd
US$ 1,24
(94,14%)
205,02M
AIEVThunder Power Holdings Inc
US$ 0,47
(87,25%)
122,71M
PASGPassage Bio Inc
US$ 1,13
(69,52%)
15,44M
EPOWSunrise New Energy Company Ltd
US$ 1,06
(45,21%)
314,9k
APLTApplied Therapeutics Inc
US$ 2,03
(-76,31%)
43,9M
TGLTreasure Global Inc
US$ 0,2944
(-29,08%)
1,85M
PROCProcaps Group SA
US$ 1,51
(-27,75%)
106,08k
SHOTWSafety Shot Inc
US$ 0,104
(-20,00%)
1,43k
MONDMondee Holdings Inc
US$ 0,7102
(-19,59%)
297,63k
PRZOParaZero Technologies Ltd
US$ 1,24
(94,14%)
202,48M
NVDANVIDIA Corporation
US$ 138,25
(2,15%)
140,34M
AIEVThunder Power Holdings Inc
US$ 0,47
(87,25%)
122,71M
RGTIRigetti Computing Inc
US$ 3,05
(27,08%)
115,6M
MARAMARA Holdings Inc
US$ 27,42
(1,86%)
88,39M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock